Navigation Links
Glysure Appoints Justine McQuillan as European Director of Clinical Affairs
Date:9/25/2013

OXFORD, England, September 25, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced the appointment of Justine McQuillan as its European Director of Clinical Affairs. In this newly established position, McQuillan is leading European clinical regulatory trials of GlySure's CBGM technology, which the company expects to complete this fall.

McQuillan has extensive clinical, operational and commercial experience within the MedTech industry, with expertise in the development, evaluation and validation, regulatory clearance and marketing of medical devices and supporting services. She spent eight years at Medicsight PLC, having most recently served as Vice President of Clinical Development. In this role, McQuillan planned, implemented and managed the clinical regulatory strategy to support European, U.S., Chinese and Japanese submissions for regulatory clearance of the company's computer-aided detection medical image analysis products.

"McQuillan's knowledge and experience in successfully guiding a company from R&D through regulatory trials and all the way through to commercialization are the exact qualities we need at this critical juncture of our development," said GlySure CEO Chris Jones. "In addition to leading efforts to secure a CE mark, McQuillan will be working closely with our U.S. trial sites to prepare for U.S. FDA 510(k) regulatory trials."

McQuillan holds a Master of Business Administration from the University of Westminster, London, a Post-graduate Diploma in Management from University of London, and a Diploma in Medical Diagnostic Imaging from Auckland School of Radiography, New Zealand.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Earns ISO 13485 Certification
2. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
3. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Cornerstone ... company, today presented data from two Phase I ... sessions at the 58th annual meeting of the ... San Diego, California . The two datasets ... with acute myeloid leukemia (AML) and T-cell non-Hodgkin,s ...
(Date:12/5/2016)... 5, 2016  Pennsylvania Physician General Dr. Rachel ... Gary Tennis today filled prescriptions for naloxone, ... in York to demonstrate how ... Levine as a prescription to acquire naloxone at any ... to remember that any Pennsylvanian can walk up to ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
Breaking Medicine News(10 mins):